Blog - Page 4153 of 5482

MondayNov 03, 2008 5:45 am

Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to becoming the global leader in regenerative medicine. The company focuses on providing patients with new options for reconstructive and aesthetic surgery, developing treatments for cardiovascular disease, and banking adipose-derived, adult stem and regenerative cells (ADRCs). To meet its objective, Cytori developed Celution® Technology to separate and concentrate a patient’s own ADRCs for delivery back to the same patient in a single surgical procedure. For further information, visit the Company's web site at www.cytoritx.com.

MondayNov 03, 2008 5:45 am

Targanta Therapeutics Corporation (NASDAQ: TARG)

Targanta Therapeutics Corporation (NASDAQ: TARG), a biopharmaceutical company, is dedicated to developing and commercializing innovative antibiotics that treat serious infections in the hospital and other institutional settings. The company’s lead antibiotic, oritavancin, is designed to treat serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Additionally, Targanta is developing multiple antibacterial agents, including an oral version of oritavancin targeting Clostridium difficile-related conditions. For further information, visit the Company's web site at www.targanta.com.

MondayNov 03, 2008 5:44 am

Cytomedix, Inc. (AMEX: GTF)

Cytomedix, Inc. (AMEX: GTF), a biotechnology company, is focused on developing, selling and licensing regenerative biological therapies. Their AutoloGel(tm) System, a device used to produce platelet rich plasma gel derived from the patient's own blood, has been cleared by the Food and Drug Administration (``FDA'') for use on a variety of exuding wounds. Currently, the Company is executing a multi-faceted strategy to infiltrate the chronic wound market with its AutoloGel(tm) System. For further information, visit the Company's web site at www.cytomedix.com

MondayNov 03, 2008 5:44 am

Synvista Therapeutics, Inc. (AMEX: SYI)

Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company's web site at www.alteon.com.

MondayNov 03, 2008 5:44 am

Cytokinetics, Incorporated (NASDAQ: CYTK)

Cytokinetics, Incorporated (NASDAQ: CYTK), a biopharmaceutical company, is devoted to the discovery, development and commercialization of innovative small molecule drugs. The company’s cardiovascular disease program is focused on cardiac myosin, which is a motor protein vital to cardiac muscle contraction. CK-1827452, Cytokinetics' lead compound from this program, is a small molecule cardiac myosin activator that has entered Phase II clinical trials for the treatment of heart failure. For further information, visit the Company's web site at www.cytokinetics.com.

MondayNov 03, 2008 5:44 am

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company, has dedicated their efforts to discovering, developing, and commercializing innovative pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. The company has an exceptional chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with innovative chemical structures and distinct mechanisms of action. For further information, visit the Company's web site at www.syntapharma.com.

MondayNov 03, 2008 5:43 am

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN)

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is a Chinese company that is engaged in the manufacture and sale of a wide range of neutraceutical products. Sunwin’s product lines include zero-calorie all natural Stevia sweeteners, traditional Chinese medicines, as well as veterinary medicines and animal feeds prepared from 100% organic herbal ingredients. Sunwin has built an integrated global organization with the sourcing and production capabilities to satisfy the needs of global consumers. For further information, visit the company website at: www.sunwininternational.com.

MondayNov 03, 2008 5:43 am

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company's web site at www.cyclacel.com.

MondayNov 03, 2008 5:43 am

SuperGen, Inc. (NASDAQ: SUPG)

SuperGen, Inc. (NASDAQ: SUPG) is focused on building a global, sustainable business by developing and commercializing new drug candidates for oncologists, hematologists, and their patients. The company’s staff is made up of talented individuals who recognize the incredible challenges of drug development. Although some work along and other on teams, each employee brings a distinct perspective to his or her job and is focused on the goal of bringing better products to cancer patients in need. For further information, visit the Company's web site at www.sunesis.com.

MondayNov 03, 2008 5:43 am

CV Therapeutics, Inc.’s (NASDAQ: CVTX)

CV Therapeutics, Inc.’s (NASDAQ: CVTX) primary focused is on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. The company is devoted to discovering new solutions for the unmet medical needs of patients. By emphasizing on discovery science and small molecule therapeutics, the company’s drug candidates are usually able to be produced by conventional pharmaceutical manufacturing methods. For further information, visit the Company's web site at www.cvt.com.

Site Search

Company Search

Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Targanta Therapeutics Corporation (NASDAQ: TARG)

Cytomedix, Inc. (AMEX: GTF)

Synvista Therapeutics, Inc. (AMEX: SYI)

Cytokinetics, Incorporated (NASDAQ: CYTK)

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

SuperGen, Inc. (NASDAQ: SUPG)

CV Therapeutics, Inc.’s (NASDAQ: CVTX)

Market Basics

Newsletter Publishers

Public Companies